Β-Blockers and angiotensin-converting enzyme inhibitors with sublingual immunotherapy: are risks related to individual product safety profile?. Issue 4 (August 2020)

• Record Type: Journal Article
• Authors: Smith, Derek M.; Coop, Christopher A.; Freeman, Theodore M.
• Is Part Of: Current opinion in allergy and clinical immunology. Volume 20:Issue 4(2020:Aug.)
• Publication Date: 2020-08
• Subjects: angiotensin-converting enzyme inhibitor -- anaphylaxis -- β-blocker -- sublingual immunotherapy -- sublingual immunotherapy; Allergy -- Periodicals; Clinical immunology -- Periodicals; Hypersensitivity; Immunity; Immune System Diseases; Allergy and Immunology; 616.079
• DOI: 10.1097/ACI.0000000000000657
• Languages: English
• ISSNs: 1528-4050

Abstract

Abstract : Purpose of review: The objective of this article is to review the available literature regarding the risks associated with sublingual immunotherapy and angiotensin-converting enzyme (ACE) inhibitors or β-blocker use. It also evaluates for any differences in these risks among the available sublingual immunotherapy (SLIT) tablets. Recent findings: A literature search was conducted in PubMed to identify peer-reviewed articles using the following keywords: anaphylaxis, ACE inhibitor, β-blocker, and sublingual immunotherapy. Minimal data exist regarding their safety of SLIT in patients concomitantly taking ACE inhibitors or β-blockers. The adverse reaction rates seem similar between SLIT products. Summary: A risk-versus-benefit discussion should be communicated with the patient taking a β-blocker before beginning SLIT but automatic denial of SLIT to these patients is not warranted.